Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.

ABSTRACT:

Objectives

Gout is one of the most common forms of arthritis. It is well established that urate-lowering therapy that aims for a serum urate less than at least 0.36 mmol/l (6 mg/dl) is required for the successful management of gout. Allopurinol, a xanthine oxidase (XO) inhibitor, is the most commonly used urate-lowering therapy. However, many patients fail to achieve the target serum urate on allopurinol; these patients can be considered to have "inadequate response" to allopurinol. Herein, we examine the potential mechanisms and implications of inadequate response to allopurinol.

Methods

The literature was reviewed for potential causes for failure to reach target serum urate in patients receiving allopurinol.

Results

The two most common causes of inadequate response

SUBMITTER: Stamp LK 

PROVIDER: S-EPMC4225179 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature